Combination of anti-ICAM-1 and anti-LFA-1 monoclonal antibody therapy prolongs allograft survival in rat hind-limb transplants

Journal of Reconstructive Microsurgery

Volumn 17, Issue 7, 2001, Pages 511-517

  Ozer, K ^a   Siemionow, M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ICAM 1 MAb; LFA 1 MAb; Limb transplantation; Rat hind limb cremaster transplantation model; Transplant rejection

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREMASTER MUSCLE; DOSE RESPONSE; EDEMA; ENDOTHELIUM; GRAFT SURVIVAL; HINDLIMB; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROCIRCULATION; PRIORITY JOURNAL; RAT; TRANSPLANTATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; DATA INTERPRETATION, STATISTICAL; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HINDLIMB; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICROCIRCULATION; RATS; RATS, INBRED BN; RATS, INBRED LEW; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034758109     PISSN: 0743684X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17753     Document Type: Article

References (14)

1. Adhesion receptors of the immune system
2. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
3. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation: A pilot study
4. Intercellular immune adhesion molecules in human liver transplants: Overview on expression patterns of leukocyte receptor and ligand molecules
5. Anti-ICAM-1 antibodies protect allografts against microvascular and parenchymal cell damage
6. Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies
7. The effect of anti-ICAM-1 monoclonal antibody treatment on the transplantation of the small bowel in rats
8. In vivo effects of monoclonal antibody to ICAM (CD54) in nonhuman primates with renal allografts
9. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) MAb in renal allograft recipients
10. Role of ICAM-1 and LFA-1 in cardiac allograft rejection of the rat
11. Prevention of fetal bowel allograft rejection by combined treatment with anti-ICAM-1 and anti-LFA-1 antibodies
12. CD 28 and LFA-1 contribute to Cyclosporin A-resistant T cell growth by stabilizing the IL-2 mRNA through distinct signaling pathways
13. Peptides from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture
14. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European anti-ICAM-1 renal transplant study group